Array BioPharma Chief Scientific Officer Kevin Koch is leaving the biotech after 15 years, news that sent the company's shares down more than 5% on Thursday morning.
Three months after in-licensing a preclinical cancer drug from Array BioPharma ($ARRY), the upstart biotech Loxo Oncology announced that it has a $33 million Series A lined up to fund the work ahead.
Shares of Array BioPharma took a nasty dive Wednesday evening after Amgen pulled the plug on an ambitious four-year-old partnership to develop new Type 2 diabetes drugs. The company said it will have to ax 50 workers--20% of its staff--in response.
The arrangement with Array represents a relatively small upfront bet for Celgene, which has just forked over $100 million for an option to buy Acetylon and the Boston startup's HDAC6 inhibitor in early clinical development for myeloma.
Array BioPharma has another asset on deck for a potential partnership. The company has touted upbeat Phase II data for an experimental drug in patients with allergic asthma, and the company plans to seek a partner to fund further studies.
A New York-based biotech startup funded by Aisling Capital has stepped up to partner with Array BioPharma on a preclinical cancer program. Loxo Oncology will fund the preclinical work before taking over responsibility for the clinical trials.
As investigators narrow their search for effective remedies for more narrowly defined patient populations, clinical trials in oncology have sometimes begun to look more like the investigative work you find in the rare-disease arena. And nowhere was that more evident than in an ASCO presentation on the efficacy of AstraZeneca's selumetinib for rare cases of advanced melanoma in the eye.
Back in the spring of 2010, James Lieberman landed a hot biotech stock tip. Unfortunately for him, though, it allegedly came from his boss and concerned his own company--Array BioPharma.
Array BioPharma touted its latest mid-stage study of a key pain drug as an unqualified success, beating a placebo and hitting its primary endpoint when tested in patients suffering from osteoarthritis. But when investors dug down into the release and found that its experimental med did no better than a standard treatment, its shares slid more than 11%.
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.